secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001213900-24-083203
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed FY2024 net loss $7.7M; revenue up 11% to $4.6M; cash $6.6M
----------------------------------------------------------------

- Net loss of $7.7M vs $7.9M prior year; diluted EPS loss $1.01 vs $3.25.
- Revenue from BayMedica segment $4.6M, up 11% YoY; gross profit $1.1M.
- Cash, equivalents, and short-term investments $6.6M at June 30, 2024.
- R&D and patent expenses $3.8M; G&A $5.3M, down from $5.8M.
- Pipeline update: INM-901 Alzheimer's program advancing; INM-089 dry AMD preclinical data positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024083203/0001213900-24-083203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024083203/ea0216150-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-083203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer